16,540 Medtronic PLC $MDT Shares Purchased by Asset Management One Co. Ltd.

Key Points

• Asset Management One increased its Medtronic stake by 2.9%, purchasing 16,540 shares to own 579,803 shares valued at approximately $50.0 million. Institutional investors collectively own 82.06% of the company.
• Analysts maintain a “Moderate Buy” consensus on MDT, with an average price target of $102.88; ratings include 18 Buys, nine Holds and one Sell.
• Medtronic recently exceeded quarterly earnings and revenue expectations, while paying a $0.72 quarterly dividend. However, insiders sold 61,903 shares worth about $5.9 million over the past 90 days.

Asset Management One Co. Ltd. grew its stake in Medtronic PLC (NYSE:MDT - Free Report) by 2.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 579,803 shares of the medical technology company's stock after purchasing an additional 16,540 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Medtronic were worth $50,031,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of MDT. John Boyer Inc. purchased a new stake in Medtronic in the 3rd quarter valued at about $44,000. Latitude Advisors LLC bought a new position in shares of Medtronic during the 3rd quarter worth approximately $55,000. SYM FINANCIAL Corp boosted its stake in shares of Medtronic by 45.3% in the 3rd quarter. SYM FINANCIAL Corp now owns 5,079 shares of the medical technology company's stock worth $438,000 after buying an additional 1,584 shares during the last quarter. Ashton Thomas Securities LLC boosted its stake in shares of Medtronic by 51.2% in the 3rd quarter. Ashton Thomas Securities LLC now owns 6,787 shares of the medical technology company's stock worth $586,000 after buying an additional 2,297 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its stake in shares of Medtronic by 3.5% in the 3rd quarter. Park Avenue Securities LLC now owns 55,811 shares of the medical technology company's stock worth $4,816,000 after buying an additional 1,906 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

Analyst Ratings Changes

MDT has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating on shares of Medtronic in a report on Thursday, September 17th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $92.00 price target on shares of Medtronic in a report on Thursday, September 3rd. Robert W. Baird boosted their price objective on Medtronic from $91.00 to $100.00 and gave the stock a "neutral" rating in a research report on Wednesday, September 2nd. TD Cowen reissued a "buy" rating and issued a $110.00 price objective on shares of Medtronic in a research report on Wednesday, September 30th. Finally, Barclays upgraded Medtronic to a "hold" rating in a research note on Wednesday, October 7th. Eighteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $102.88.

Insiders Place Their Bets

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the firm's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares of the company's stock, valued at $10,167,936. This trade represents a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,903 shares of company stock valued at $5,889,203 over the last ninety days. 0.27% of the stock is currently owned by insiders.

Medtronic Stock Up 0.8%

Medtronic stock opened at $94.70 on Thursday. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The firm has a 50 day moving average price of $91.56 and a 200-day moving average price of $88.35. The company has a market capitalization of $121.14 billion, a P/E ratio of 23.33, a P/E/G ratio of 2.23 and a beta of 0.55. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic's quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic's dividend payout ratio (DPR) is currently 70.94%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Exchange-traded funds purchased approximately $18 million of Medtronic shares on October 26, providing evidence of institutional demand and potentially supporting the stock. ETFs Bought $18.0 Million of Medtronic
• Positive Sentiment: Analyst commentary highlights Medtronic’s broader growth opportunities and relatively attractive valuation. Potential drivers include new product launches, procedure recovery and expansion in higher-growth medical-device markets. Medtronic: Broader Growth, Attractive Valuation
• Positive Sentiment: The global leadless-pacemaker market is forecast to expand at a 12.8% compound annual growth rate through 2036, reaching $4.87 billion. Medtronic’s presence in cardiac rhythm management gives it exposure to this long-term opportunity, although the report is industry-wide rather than company-specific. Global Leadless Pacemakers Market Forecast
• Neutral Sentiment: Medtronic’s upcoming fiscal second-quarter 2027 report is the key near-term catalyst. Analysts expect a low-single-digit profit decline, while the company’s latest guidance calls for quarterly EPS of $1.32–$1.34 and full-year EPS of $5.94–$6.00. Results and guidance could determine the next major move. Medtronic’s Q2 2027 Earnings: What to Expect
• Negative Sentiment: Medtronic’s latest dividend increase extended its 49-year streak, but the relatively modest raise may be less compelling to income investors than faster payout growth from Abbott and Johnson & Johnson. Medtronic Raised Its Dividend Again

Medtronic Profile

Medtronic plc NYSE: MDT is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company's offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.